

SAUDI LYMPHOMA/ MYELOMA 2026

HEMATOPATHOLOGY OVERVIEW 2026

09-10 OCT 2026 | 8:30 - 5:00 PM

NOVOTEL DHAHRAN HOTEL & RESIDENCES

Organized by:
SAUDI LYMPHOMA GROUP
In collaboration with
SS BMT
Saudi Society of Bone Marrow Transplantation

VISIT US AT:
<https://ssbmt.org>

www.ssbmt.org | www.ssbmt.org | www.ssbmt.org | www.ssbmt.org | www.ssbmt.org | www.ssbmt.org | www.ssbmt.org | www.ssbmt.org | www.ssbmt.org | www.ssbmt.org

SCIENTIFIC PROGRAM

SAUDI LYMPHOMA/MYELOMA 2026

Friday, 09 October 2026

Time	Mins.	Topic	Speaker
8:00 – 8:30	30'	Registration	
8:30 – 8:35	05'	Welcome Remarks and Program Overview	Mubarak Almansour
Session One: Abdullah Al Saleh / Solaf Kanfar / Wael Alanazi			
8:35 – 9:00	25'	What are the frontline treatment strategies for Multiple Myeloma in 2026 for transplant-eligible and ineligible?	Khalil Farsi (OM)
9:00 – 9:25	25''	RRMM Current Landscape and Future Directions	Omar Al Abduljalil (KSA)
9:25 – 9:50	25'	CAR-T vs. Bispecific therapy for relapsed Multiple Myeloma, which one and when?	Majed Alahmadi (KSA)
9:50 – 10:00	10'	Discussion	
10:00 – 10:15	15'	Coffee Break	
10:15 – 10:45	30'	GSK SATELLITE SYMPOSIUM	TBA (GSK) / Moderator
10:45 – 11:15	30'	SATELLITE SYMPOSIUM (Pharma-Industry)	TBA / Moderator
11:15 – 1:30	135'	Juma'ah Prayer and Lunch Break (12:00 PM)	
Session Two: Musa Al Zahrani, Abdulkareem Alqarni / Aamer Bugnah			
1:30 – 2:00	30'	Frontline mantle cell lymphoma: do we still need autologous transplant?	Toby Eyre (UK)
2:00 – 2:30	30'	GSK SATELLITE SYMPOSIUM	TBA (GSK)
2:30 – 3:00	30'	Follicular lymphoma: second-line therapy is being rewritten	Ann Lacasce (USA)
3:00 – 3:15	15'	Coffee Break	
Session Three: Ayman Alhejazi / Ghazi Alotaibi /			
3:15 – 3:45	30'	IASO SATELLITE SYMPOSIUM	TBA (IASO)
3:45 – 4:15	30'	Smoldering Multiple Myeloma	Maria Victoria Mateos (ES)
4:15 – 4:45	30'	Summary of new response criteria in Multiple Myeloma	Shaji Kumar (USA)
4:45 – 5:00	15'	Coffee Break	
Session Four: Ayman Ibrahim / Manar Abdulbaqi / Khalid Aldosari			
5:00 – 5:30	30'	Early-stage Hodgkin Lymphoma: How immunotherapy is changing the treatment landscape.	Stephan Ansell (USA)
5:30 – 6:00	30'	R/R CLL: best sequencing strategy	John Allan (USA)
6:00 – 6:30	30'	Best management strategy in R/R T-cell-rich B-cell lymphoma	Tycel Phillips (USA)
6:30 --		Discussion – End of Day 1	

SAUDI LYMPHOMA/ MYELOMA 2026

HEMATOPATHOLOGY OVERVIEW 2026

09-10 OCT 2026 | 8:30 - 5:00 PM

NOVOTEL DHAHRAN HOTEL & RESIDENCES

Organized by:

SAUDI LYMPHOMA GROUP
Saudi Lymphoma Group

In collaboration with
SS BMT
Saudi Society of Bone Marrow Transplantation

VISIT US AT:

<https://ssbmt.org>

SAUDI LYMPHOMA GROUP | SAUDI LYMPHOMA GROUP | SAUDI LYMPHOMA GROUP | SAUDI LYMPHOMA GROUP | SAUDI LYMPHOMA GROUP | SAUDI LYMPHOMA GROUP | SAUDI LYMPHOMA GROUP | SAUDI LYMPHOMA GROUP | SAUDI LYMPHOMA GROUP | SAUDI LYMPHOMA GROUP

SCIENTIFIC PROGRAM

HEMATOPATHOLOGY OVERVIEW 2026

Saturday, 10 October 2026

Time	Mins.	Topic	Speaker
Session One: Dr. Mohammed Al Mohammadi Dr. Sameerah Al Safwani			
8:30 – 8:35	05'	Welcome Remarks and Program Overview	Ahmed Al-Bahrani, MD
8:35 – 8:55	20'	Expect the unexpected: intriguing cases in hematopathology	Reem Al Rabeh, MD
8:55 – 9:15	20'	Flowcytometry in the diagnosis of hematological malignancies	Mariam Al Ghazal, MD
9:15 – 9:35	20'	Diagnostic classification of myeloid neoplasm: WHO 5th vs ICC 2022 for myeloid neoplasm	Maher Aljohani, MD
9:35 – 9:45	10'	Discussion	
9:45 – 10:00	15'	Coffee Break	
Session Two: Dr. Abdulmajeed Al Abdullateef and Dr. Fatema Al Ghanim			
10:00 – 10:20	20'	From screening tests to precision diagnosis of acquired and congenital coagulopathies	Rabab Al Dawood, MD
10:20 – 10:40	20'	Diagnostic strategies and challenges in platelet function testing	Rahaf Altahan, MD
10:40 – 11:00	20'	The Evolving landscape of factor XIII testing: method, pitfalls, and best practices	Mohammed Al Sharif, MD
11:00 – 11:20	20'	Transfusion challenges in multiple myeloma	Ammar Alsughayir, MD
11:20 – 11:30	10''	Discussion	
11:30 – 1:00	90'	Prayer and Lunch Break (12:00PM)	
Session Three: Dr. Ahmed Al Bahrani and Dr. Haifa Al Muhtarish			
1:00 – 1:20	20'	Distinguishing hairy cell leukemia from splenic marginal zone lymphoma: diagnostic pearls for the hematopathologist	Mona Alfaraj, MD
1:20 – 1:40	20'	New updates in AML, Measurable residual disease a consensus approach from ELN-MRD working group	Heba Raslan, MD
1:40 – 2:00	20'	MPD – Myelofibrosis	Ahmed Al Rajjal, MD
2:00 – 2:10	10'	Discussion	
2:10 – 2:25	15'	Coffee Break	
Session Four: Dr. Mukhtar Buhlaiga and Dr. Naif Bin Muhanaa			
2:25 – 2:45	20'	The ultimate Transfusion puzzle: strategies for anti-Rh17 management.	Fatma Aldarweesh, MD
2:45 – 3:05	20'	Evolving Practice in Transplant & Cellular Therapies	Ahmed Al Bahrani, MD
3:05 – 3:25	20'	Updates on mismatch unrelated hematopoietic stem cell transplantation	Mohammed Awaji, PhD
3:25 – 3:35	10'	Discussion and Closing Remarks	Ammar Alsughayir, MD
3:35--		End of Day 2	